Genetix Biotherapeutics

On Rare Disease Day, we recognize the many individuals and their families living with rare diseases. We also acknowledge the resilience required to navigate conditions that are often misunderstood, underdiagnosed, and under-resourced.    At Genetix, we remain grounded in our commitment to the patients and communities affected by severe rare diseases.    Today, we join the broader rare disease community in raising awareness and reaffirming the importance of sustained progress.     #RareDiseaseDay #Hematology #SickleCellDisease #CGT

February is Black History Month—a time to honor lived experiences, acknowledge disparities, and recommit to the work that remains.    Sickle cell disease disproportionately impacts the Black community, and longstanding inequities in healthcare access continue to shape patient experiences today.    At Genetix, we recognize that delivering our transformative therapies to patients living with sickle cell disease is only part of the work that needs to be done. Partnering with communities, healthcare providers, and patient advocates is essential to addressing barriers to equity in care.    #BlackHistoryMonth #Hematology #SickleCellDisease 

The Genetix team is onsite at Tandem 2026 alongside the broader genetic therapy community. Visit us at Booth 431 to connect with the team and learn more about our work advancing transformative therapies for people living with sickle cell disease and beta-thalassemia. We will be sharing and discussing two posters led by Anjulika Chawla and Vinod Prasad, highlighting real-world data and insights from clinical and commercial experience. Our focus remains on transforming lives through curative therapy—with laser-focus on commercial execution, scaling access, and an improved treatment experience. #Tandem2026 #Hematology #CGT

Genetix will be onsite at TANDEM 2026 in Salt Lake City (Feb 4-7). Visit us at Booth 431 to meet the team and learn more about our work advancing genetic therapies for sickle cell disease and beta-thalassemia. Two posters featuring Genetix real-world data will be on display: Vinod Prasad et al. on “Accelerating Access to Gene Therapy: Lessons from Commercial Implementation in Sickle Cell Disease andTransfusion-Dependent Thalassemia” Anjulika Chawla et al. on “Pre-Transplant Immunomodulation Enables Successful Infusion of Genetically Modified Cells in a Sickle Cell Patient.” We look forward to engaging with the community and sharing updates on our progress. #Tandem2026 #Hematology #SickleCellDisease #BetaThalassemia

Martin Luther King, Jr. spoke often about equality. Unfortunately, inequality in healthcare is still a reality for many people. At Genetix, we work every day to make curative therapies available to the patients we serve, and we are committed to advancing equitable access for individuals impacted by sickle cell disease and beta-thalassemia. This MLK Day, take a moment to reflect on the legacy of Dr. King’s teachings and the powerful messages he shared on freedom, equality, and civil rights. #MLK #MLKday #Genetix

Happy Holidays from the entire team at Genetix Biotherapeutics. 2025 has been a pivotal and exciting year, marking the start of a groundbreaking new era for our company and meaningful progress towards our mission of transforming lives through curative therapies. We remain committed to delivering our life-changing genetic therapies for patients living with severe rare diseases and are eager to build on this year's substantial growth as we head into 2026. We are deeply grateful for the dedication of our employees, our partners, and the patients we have the privilege to serve. Wishing you all a joyous and restful holiday season.

Genetix is sharing new data today at the 67th ASH Annual Meeting in Orlando. Happening today at 4:00pm EST, Anju Chawla, MD and VP of Clinical Science, will be presenting real-world patient experience data from U.S. commercial gene therapy implementation. This analysis reinforces the value of durable, one-time gene therapy for the treatment of sickle cell disease and beta thalassemia. Learn more here: https://lnkd.in/eyGU-GtY and visit us at Booth 1261. American Society of Hematology

Join the Genetix team in Orlando for the 67th ASH Annual Meeting (Dec 6-9). We remain deeply committed to delivering transformative therapies for patients with sickle cell disease and beta thalassemia. Earlier this week, Genetix participated in ASH’s exclusive press program to share recent patient experience data from U.S. commercial gene therapy implementation. Learn more here: https://lnkd.in/eRc8K_2p. The full data will be presented on December 8th at 4pm EST. Stop by Booth 1261 to connect with our team. American Society of Hematology

Join the Genetix team in Orlando for the 67th ASH Annual Meeting (Dec 6-9). We remain deeply committed to delivering transformative therapies for patients with sickle cell disease and beta thalassemia. Earlier this week, Genetix participated in ASH’s exclusive press program to share recent patient experience data from U.S. commercial gene therapy implementation. Learn more here: https://lnkd.in/eRc8K_2p. The full data will be presented on December 8th at 4pm EST. Stop by Booth 1261 to connect with our team. American Society of Hematology